JOURNAL OF IMMUNOTHERAPY

简称 J IMMUNOTHER ·UNITED STATES ·出版周期 Monthly ·年均收录 44 篇

2.9

最新影响因子

3.00%

自引率

一般

投稿难度

较慢,6-12周

审稿周期

期刊简介

JOURNAL OF IMMUNOTHERAPY是一本专注于免疫治疗领域的学术期刊，ISSN号为1524-9557，由Lippincott Williams & Wilkins出版社出版，出版地为美国，出版周期为月刊。该期刊的影响因子根据年份有所不同，最新数据需查询官方来源，目前被SCI收录，中科院分区情况需参考最新分区表。期刊为非OA（开放获取）模式。其发文特点主要集中在肿瘤免疫治疗、免疫调节、免疫相关疾病的基础与临床研究，涵盖免疫检查点抑制剂、CAR-T细胞疗法、疫苗开发等前沿领域。杂志质量较高，审稿流程严格，但投稿竞争激烈，拒稿率可能较高，需注意研究创新性和临床相关性。总体而言，该期刊是免疫治疗领域的重要参考，适合高质量研究成果的发表。

影响因子趋势

近期发表

Brief Communication: LSD1 Inhibition Enhances Susceptibility of Primary AML Cells for NK Cell-Mediated Killing 2026-09-16

Armoring CAR-T Cells Against Exhaustion: Engineering Strategies for Glioblastoma 2026-08-27

Immune Checkpoint Inhibitor-Associated Hemophagocytic Lymphohistiocytosis: Clinical Presentation and Outcomes in Three Patients 2026-08-14

IGF2BP3-Mediated m6A Modification of OLR1 mRNA Promotes Immune Evasion in CRC via the PI3K/AKT/mTOR Pathway 2026-08-13

Local Therapy for Isolated Residual Metastatic Melanoma and Renal Cell Carcinoma Following Immune Checkpoint Inhibition Leading to Long-Term Remission 2026-08-12

Identifying Patients at Risk for Immune Checkpoint Inhibitor-Induced Colitis: Evidence From a Real-World Oncology Cohort 2026-08-06

Internalization-Dependent EGFR-Targeted Photoactivation by Cetuximab-I21 Conjugates 2026-06-23

Clinical Features, Treatment, and Outcomes of Nivolumab-induced Autoimmune Hemolytic Anemia 2026-06-15

Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study 2026-06-10

Talimogene Laherparepvec Response in Recurrent Melanoma During Corticosteroid Replacement for Immune Checkpoint Inhibitor–Induced Adrenal Insufficiency: A Case Report 2026-06-08